The predictive value of CK-MB on the curative effect of urokinase combined with LMWH calcium in AMI.

Autor: Tang H; Department of Cardiology, Wugang People's Hospital, Wugang, Hunan, China., Liu Y; Department of Cardiology, Wugang People's Hospital, Wugang, Hunan, China., Yu Y; Department of Cardiology, Wugang People's Hospital, Wugang, Hunan, China., Zhou J; Department of Emergency, Wugang People's Hospital, Wugang, Hunan, China., Yang J; Department of Cardiology, Wugang People's Hospital, Wugang, Hunan, China.
Jazyk: angličtina
Zdroj: Biomarkers in medicine [Biomark Med] 2024 Dec; Vol. 18 (24), pp. 1087-1092. Date of Electronic Publication: 2024 Nov 24.
DOI: 10.1080/17520363.2024.2429367
Abstrakt: Objective: This study investigates the predictive value of CK-MB in treating acute myocardial infarction (AMI) with urokinase combined with low molecular weight heparin (LMWH) calcium.
Methods: AMI patients treated at our hospital from April 2020 to August 2022 were included in this prospective, multi-center cohort study. Patients were randomly assigned to a urokinase group or a combined treatment group (urokinase plus LMWH). CK-MB levels were measured using ELISA, and adverse reactions were recorded. The accuracy of CK-MB as a predictor was evaluated via ROC curve analysis and AUC.
Results: Before treatment, CK-MB levels were similar in both groups ( p  > 0.05). Post-treatment, levels were significantly lower in the combined group ( p  < 0.05). The combined group had a higher proportion of mild CK-MB elevation and lower moderate/severe elevations ( p  < 0.05). Adverse reaction rates were similar ( p  > 0.05). The combined treatment group showed higher effectiveness ( p  < 0.05), with better sensitivity (94%) and specificity (82%) than the urokinase group (sensitivity 89%, specificity 78%).
Conclusion: CK-MB is a valuable predictor for evaluating the efficacy of urokinase plus LMWH in AMI treatment, offering advantages in reducing CK-MB levels and improving outcomes.
Databáze: MEDLINE
Externí odkaz: